Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
NCT04751929Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, atezolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dana-Farber Cancer Institute. Started Aug 2021; status: completed.
02
Drugs
abemaciclibatezolizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04751929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751929.